Revance Announces Proposed Public Offering of Common Stock
January 15 2019 - 4:17PM
Business Wire
Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology
company developing next-generation neuromodulators for use in
treating aesthetic and therapeutic conditions (“Revance” or the
“Company”), today announced a proposed underwritten public offering
in which it will issue and sell approximately $100 million of
shares of its common stock. Revance expects that the underwriters
will be granted a 30-day option to purchase from the Company up to
an additional 15% of the shares of its common stock. The Company
intends to use the net proceeds received from its offering of
common stock for working capital and general corporate purposes,
including clinical trial and related expenses, research and
development expenses, general and administrative expenses, and
capital investments. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Goldman Sachs & Co. LLC, Cowen and Piper Jaffray are acting
as book-running managers for the proposed offering.
The securities described above are being offered by Revance
pursuant to an automatic shelf registration statement previously
filed with the Securities and Exchange Commission on December 5,
2017. The offering will be made only by means of a prospectus
supplement. When available, copies of the preliminary prospectus
supplement and accompanying prospectus relating to the proposed
public offering may be obtained by contacting Goldman Sachs &
Co. LLC, Prospectus Department, 200 West Street, New York, NY
10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by
emailing prospectus-ny@ny.email.gs.com; Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, Attn: Prospectus Department, or by emailing
PostSaleManualRequests@broadridge.com; or Piper Jaffray & Co.,
Attn: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, or by telephone at 800-747-3924, or by email
at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Revance Therapeutics, Inc.
Revance is a clinical-stage biotechnology company focused on the
development, manufacturing, and commercialization of novel
neuromodulators for multiple aesthetic and therapeutic indications.
Revance is leveraging its proprietary portfolio of botulinum toxin
type A compounds, formulated with its patented and proprietary
peptide excipient technology, to address unmet needs in large and
growing neuromodulator markets.
"Revance Therapeutics" and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
Forward-Looking Statements
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to Revance's
expectations regarding the completion of the proposed public
offering. Actual results or developments may differ materially from
those projected or implied in these forward-looking statements.
Factors that may cause such a difference include, without
limitation, risks and uncertainties related to whether or not
Revance will be able to raise capital through the sale of shares of
common stock, the final terms of the proposed offering, market and
other conditions, the satisfaction of customary closing conditions
related to the proposed public offering and the impact of general
economic, industry or political conditions in the United States or
internationally. There can be no assurance that Revance will be
able to complete the proposed public offering on the anticipated
terms, or at all. Revance will need to raise additional capital to
fund its operations and may be unable to raise capital when needed,
which would force Revance to delay, reduce or eliminate its product
development programs or commercialization efforts. You should not
place undue reliance on these forward-looking statements, which
apply only as of the date of this press release. Additional risks
and uncertainties relating to the proposed offering, Revance and
its business can be found under the heading "Risk Factors" in the
preliminary prospectus supplement (and documents incorporated by
reference therein) related to the proposed public offering filed
with the Securities and Exchange Commission. Revance expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190115005906/en/
INVESTORSRevance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellan, Inc.:John
Grimaldi, (212) 213-0006jgrimaldi@burnsmc.comorMEDIAGeneral
Media:TOGORUN:Mariann Caprino,
917-242-1087m.caprino@togorun.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2023 to Apr 2024